Overview

Neuroendocrine Carcinoma Treatment Market Overview:

Neuroendocrine tumor is a malignant and a rare disorder that covers over one percent of all the malignant disorders. Neuroendocrine carcinoma develops in different organs like intestines, kidneys, lungs, GI tract and brain. This cancer type occurs in the neuroendocrine system of humans and produces hormones that are like neuroendocrine cells. As per the America Society of Clinical Oncology, over 11,000 people in the United States are diagnosed with neuroendocrine carcinoma every year. Furthermore, as pe the U.S Surveillance Epidemiology and End Results Register, the prevalence of gastrointestinal neuroendocrine carcinoma has risen by over 300% as compared to 1981, thus offering an opportunity for neuroendocrine carcinoma treatment market growth. Additionally, growing investments in research and development for creating next-gen sequencing tools that are cost-effective and are used for developing advanced cancer therapies. With an increase in the number of clinical trials, this market is anticipated to witness substantial growth over the next few years.
There are various treatment alternatives available for the neuroendocrine carcinoma like radiation therapy, chemotherapy and surgery. 5-Fluorouracil and Streptozocin are some of the drugs that are used for treating this cancer. Many key players are constantly making efforts in developing targeted therapies, thereby propelling the proliferation of the market. Targeted drugs like Sunitinib and Everolimus are used for the treatment of this cancer. Such a variety of drug alternatives for treatment shall bolster the proliferation of the market.

Neuroendocrine Carcinoma Treatment Market

Market Segmentation:

By Site
•   Lung
•   Gastrointestinal
•   Pancreas
•   Brain
•   Others
By Diagnostic Tools
•   Biopsy
•   Imaging
•   Serology
•   Others
By Region
•   North America
•   Europe
•   Asia-Pacific
•   Latin America
•   Middle East and Africa

The market is classified into site, diagnostic tools and region. The site segment is fragmented into lung, gastrointestinal, pancreas, brain and others. The gastrointestinal segment accounted for the largest neuroendocrine carcinoma treatment market share and this can be attributed to unhealthy dietary choices leading to GI tract issues. Radiofrequency ablation is the only alternative for pancreatic neuroendocrine carcinoma tumor, and this shall bolster the augmentation of the market. On the other hand, disadvantages like tumor spread, bleeding and pancreatic fistula are predicted to restrain the market growth. The diagnostic tools segment is diversified into biopsy, imaging, serology and others. The serology segment is further divided into blood test, molecular tests, urine test and others. The imaging segment is categorised into X-ray, PET scan, CT scan and others. The increased acceptance of novel diagnostic imaging methods that are capable of detecting minute and clinically insignificant tumors shall contribute in the growth of the market.

Regional Analysis:

The North America region is expected to dominate the market, and this can be credited to the rising prevalence of NETs in the United States which has increased the investments by key market players in developing advanced cancer therapies. As per the National Health Service, 2015, over 7,900 people are identified with carcinoid tumor in the United Kingdom each year and this shall rise during the forecasted timeframe, making Europe the second highest growing markets.

Competitive Landscape:

Some of the major market players are Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Dauntless Pharmaceuticals, Hutchison MediPharma Limited, AVEO Pharmaceuticals Inc., Chiasma Inc., Aegis Therapeutics, Ispen, Progenics Pharmaceuticals, Inc., Tarveda Therapeutics, Pfizer, Jubilant Life Sciences Ltd.(Jubilant DraxImage), AbbVie Inc., Delcath Systems Inc., Exelixis, Inc.

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key market trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the global neuroendocrine carcinoma treatment market by site, by diagnostic tools and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
• To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

•   We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•   The customization Mobility Care offered are free of charge with purchase of any license of the report
•   You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com